GIGABYTE Server, through many years of design and engineering experience, offers the most competitive, high performance servers on the market
AMD and Penguin Computing have donated systems totalling seven petaflops of compute power to researchers as part of the AMD HPC Fund for COVID-19 research.
GIGABYTE continues its active development of new AMD EPYC platforms with the release of the 2U 4 Node H261-Z60, the first AMD EPYC variant of our Density Optimized Server Series
GIGABYTE a provider of server hardware for high performance computing has released two new 4U GPU servers: the 8 x SXM2 GPU G481-S80, and the 10 x GPU G481-HA0
GIGABYTE, a provider of high performance server motherboards and systems, has refreshed its AMD EPYC 1U and 2U server line-up
Robert Roe reviews the latest in accelerator technology and finds that GPUs and coprocessors will be key fixtures in the future of deep learning
Elsevier and ExactCure recently announced a collaboration to develop and offer to hospitals – without charge – drug-specific exposure models for 20 already approved medicines that are being tested as potential treatments for Covid-19.
With the world’s focus on the COVID-19 pandemic, LIMS providers are working to develop solutions tailored to assist in the testing and management of virus samples.
Researchers at Harvard Medical School (HMS) have released an open source drug discovery platform, VirtualFlow, that harnesses supercomputing power to screen potentially billions of small organic compound structures in parallel, in the hunt for promising new drug molecules.
When designing a component or system, where do you start? In days gone by, designers would literally go back to the drawing board, using their experience and expertise to develop a new concept.
Effective utilisation of computing tools is critical to both AI and HPC research, with recent projects in both fields highlighting the scientific benefit of carefully managing resources.
Advances in computer vision combined with AI computing are helping pathologists to more accurately identify subtypes of cancer - leading to better treatments for patients, explains Dan Ruderman.
